SARM1 functional polymorphisms and their contribution to ALS risk

SARM1 功能多态性及其对 ALS 风险的影响

基本信息

  • 批准号:
    10320381
  • 负责人:
  • 金额:
    $ 62.01万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-01-01 至 2025-12-31
  • 项目状态:
    未结题

项目摘要

Motor axon loss is a cardinal symptom of amyotrophic lateral sclerosis (ALS). Axon loss can be driven by a genetically encoded program in which the axon survival factors NMNAT2 and STMN2 inhibit the activity of the axon destruction factor SARM1. Recent data suggest that this program of axon self-destruction may contribute to pathology in ALS. First, aggregation of TDP-43, a hallmark of most ALS cases, results in the selective loss of mRNA encoding functional STMN2, a key axon survival factor. Second, loss of SARM1 suppresses some neurodegenerative phenotypes in a mouse ALS model that expresses pathogenic human TDP-43. Here we investigate the contribution of this axon degeneration pathway to ALS. We have defined the mechanism of action of SARM1, demonstrating that it is the founding member of a new class of NAD-cleaving enzymes. SARM1 enzyme activity is normally held in check via an autoinhibitory domain. Injury- or disease- induced loss of NMNAT2 and STMN2 disinhibits SARM1, leading to rapid NAD+ depletion, metabolic catastrophe, and axon fragmentation. Our structure-function studies of the SARM1 protein have identified mutations with a range of consequences, from constitutively active variants that promote cell death and axon loss, to dominant negative variants that are neuroprotective. These findings imply that human variants may exist that either promote or protect against neurodegeneration, and that understanding the phenotypic consequences of genetic variation requires functional studies of enzyme activity. In support of this hypothesis, we have identified several rare SARM1 variants in ALS patients, but not in controls, that have constitutive NADase activity and promote neuron death and axon loss. These variants also cause motor dysfunction and paralysis when expressed in the mouse CNS, suggesting that activating SARM1 mutations may contribute to ALS pathogenesis. Here we propose to define the function of SARM1 variants from ALS patients, controls, and the general population. These studies will allow us to categorize SARM1 variants as putatively pro-degenerative, neuroprotective, or neutral. In parallel, we will dissect the contribution of variation in components of the programmed axon destruction pathway to ALS phenotypes, alone and in combination with known ALS genetic risk-factors, in motor neurons differentiated from human induced pluripotent stem cells (iPSCs). Finally, we will investigate neurodegeneration in a mouse knock-in model carrying a Sarm1 allele equivalent to a pro- degenerative allele found in ALS patients, alone and in combination with a SOD1 model, based on a specific patient genotype that we identified. We will attempt to suppress ALS phenotypes with SARM1 inhibition via a proven gene therapy approach and with experimental small molecule inhibitors. Results of these studies will establish the relationship between the SARM1-mediated axon destruction program and ALS, and build the foundation to develop axoprotective therapeutics to treat this devastating disease.
运动轴突丧失是肌萎缩性侧索硬化症(ALS)的主要症状。轴突损失可以被驱动

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ADAM JOSEPH BLOOM其他文献

ADAM JOSEPH BLOOM的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ADAM JOSEPH BLOOM', 18)}}的其他基金

SARM1 functional polymorphisms and their contribution to ALS risk
SARM1 功能多态性及其对 ALS 风险的影响
  • 批准号:
    10533327
  • 财政年份:
    2021
  • 资助金额:
    $ 62.01万
  • 项目类别:
NOVEL APPROACHES TO INVESTIGATE GENETIC CORRELATES OF SMOKING BEHAVIORS
研究吸烟行为遗传相关性的新方法
  • 批准号:
    9246511
  • 财政年份:
    2014
  • 资助金额:
    $ 62.01万
  • 项目类别:
NOVEL APPROACHES TO INVESTIGATE GENETIC CORRELATES OF SMOKING BEHAVIORS
研究吸烟行为遗传相关性的新方法
  • 批准号:
    8828651
  • 财政年份:
    2014
  • 资助金额:
    $ 62.01万
  • 项目类别:
NOVEL APPROACHES TO INVESTIGATE GENETIC CORRELATES OF SMOKING BEHAVIORS
研究吸烟行为遗传相关性的新方法
  • 批准号:
    9039020
  • 财政年份:
    2014
  • 资助金额:
    $ 62.01万
  • 项目类别:
NOVEL APPROACHES TO INVESTIGATE GENETIC CORRELATES OF SMOKING BEHAVIORS
研究吸烟行为遗传相关性的新方法
  • 批准号:
    8634957
  • 财政年份:
    2014
  • 资助金额:
    $ 62.01万
  • 项目类别:

相似海外基金

Whole Genome Sequencing to identify novel loci in French Canadian ALS patients
全基因组测序识别法裔加拿大 ALS 患者的新基因座
  • 批准号:
    387259
  • 财政年份:
    2017
  • 资助金额:
    $ 62.01万
  • 项目类别:
    Studentship Programs
Elucidation of the optimal period of PAP therapy aiming at oral ingestion by ALS patients.
阐明针对 ALS 患者口服摄入的 PAP 治疗的最佳时期。
  • 批准号:
    19K20753
  • 财政年份:
    2016
  • 资助金额:
    $ 62.01万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
The effect of TNF-alpha on microglial induced hyperexcitation in cortical neurons of ALS patients
TNF-α对ALS患者皮质神经元小胶质细胞过度兴奋的影响
  • 批准号:
    367192
  • 财政年份:
    2016
  • 资助金额:
    $ 62.01万
  • 项目类别:
    Studentship Programs
Study of a communication support system for ALS patients based on changes in cerebral ongoing activity
基于大脑持续活动变化的ALS患者沟通支持系统研究
  • 批准号:
    15K12605
  • 财政年份:
    2015
  • 资助金额:
    $ 62.01万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Comprehensive genetic analysis of ALS-related genes in Japanese sporadic ALS patients
日本散发性ALS患者ALS相关基因综合遗传分析
  • 批准号:
    15K19485
  • 财政年份:
    2015
  • 资助金额:
    $ 62.01万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
ALS4 mice show TDP-43 protein mislocalization in motor neurons characteristic of sporadic ALS patients; suggesting this model is likely to reveal important patho-mechanistic disease insights
ALS4 小鼠在运动神经元中显示 TDP-43 蛋白错误定位,这是散发性 ALS 患者的特征;
  • 批准号:
    nhmrc : 1045520
  • 财政年份:
    2013
  • 资助金额:
    $ 62.01万
  • 项目类别:
    NHMRC Project Grants
Study of restoration process of the living environments of bereaved families that had undertaken long-term at-home care for ALS patients
长期居家护理ALS患者家属生活环境恢复过程研究
  • 批准号:
    24760510
  • 财政年份:
    2012
  • 资助金额:
    $ 62.01万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Microarray analysis in spinal cords of sporadic ALS patients with cell-type specific transcriptome
散发性 ALS 患者脊髓中细胞类型特异性转录组的微阵列分析
  • 批准号:
    24591259
  • 财政年份:
    2012
  • 资助金额:
    $ 62.01万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A pathological study of impaired cytoplasmic-nuclear transport impairment infamilial ALS patients harboring FUS mutatio
携带FUS突变的家族性ALS患者细胞质-核转运受损的病理学研究
  • 批准号:
    23790997
  • 财政年份:
    2011
  • 资助金额:
    $ 62.01万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
MODEL FOR THE PROMOTION OF A BARRIER-FREE MIND IN THE FAMILY CAREGIVER OF ALS PATIENTS
促进 ALS 患者家庭护理人员无障碍心态的模型
  • 批准号:
    23593266
  • 财政年份:
    2011
  • 资助金额:
    $ 62.01万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了